Michael J. Morris, MD, discusses the mechanism of action for AB001, a PSMA-targeted radioligand therapy for patients with mCRPC.
Michael J. Morris, MD
Advertisement
Michael J. Morris, MD, is a medical oncologist and the prostate cancer section head at Memorial Sloan Kettering Cancer Center in New York, New York.
Articles by Michael J. Morris, MD
Advertisement
Latest Updated Articles
Michael Morris, MD, on the mechanism of action for AB001 in mCRPCOctober 14th 2025
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
3
FDA approves cefepime and zidebactam for complicated UTI
4
FDA updates in urology: May 2026
5